Bristol-Myers Squibb Agrees to Purchase Amira Pharmaceuticals

Publication
Article
Oncology & Biotech NewsAugust 2011
Volume 5
Issue 8

Bristol-Myers Squibb has agreed to purchase Amira Pharmaceuticals, a privately held biotech company, for $325 million and potential additional milestone payments of $150 million.

bristol-myers squibb

Bristol-Myers Squibb has agreed to purchase Amira Pharmaceuticals, a privately held biotech company, for $325 million and potential additional milestone payments of $150 million. BMS plans to retain Amira’s scientists, who will continue to work at Amira’s company’s headquarters in San Diego, California.

Pfizer Inc and Icagen Inc have entered into a merger agreement. Pfizer currently owns 11% of Icagen’s shares and will acquire the remaining 8.3 million shares at $6 each. The total value of the transaction is estimated at $56 million.

Novartis reported that its net sales rose to $14.9 billion, an increase of 27%. Recently launched products increased 46% over the previous year’s quarter and contributed $3.8 billion to total net sales for the company.

Johnson & Johnson announced that its second-quarter profits dropped nearly 20% from the same time 1 year ago. The company said that this loss was not unexpected and that its earnings still came in above Wall Street’s expectations. Recall costs and restructuring charges, especially within J&J-owned McNeil Consumer Healthcare, were responsible for the change. Secondquarter earnings were $2.8 billion compared to $3.45 billion a year ago. J&J has also acquired Synthes, a Swiss manufacturer of orthopedic implants, for $21.3 billion.

Adamis Pharmaceuticals has received a patent for its APC-100 compound, which is used in the treatment of early- and late-stage prostate cancer. The company has also received FDA approval to begin phase I/IIa clinical studies of APC-100 in men with castration- resistant prostate cancer. According to the company, APC-100 inhibits the growth of prostate cancer cells, delays the progression of disease, and prevents the recurrence of prostate cancer.

AstraZeneca and PTC Therapeutics will team up in a research collaboration and license agreement for the application of PTC’s proprietary GEMS (gene expression modulation by small molecules) technology. According to the companies, GEMS is a novel technology for the identification of small molecules that modulate posttranscriptional control mechanisms. AstraZeneca will make an undisclosed cash payment up-front for research funding and for the initiation of the first target in the collaboration.

Eli Lilly’s profits fell to $1.2 billion, or $1.07 per share, in the second quarter. This is down from $1.35 billion, or $1.22 per share, at the same time last year. However, the company reports that revenues rose to $6.25 billion, a 9% increase.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "